EMA Tackles Complexities Introduced By Literature Monitoring Service
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
You may also be interested in...
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.
The European Medicines Agency is inviting feedback from pharmaceutical companies using its medical literature monitoring service to gauge if they are satisfied with the operation of this new tool, which was created under the provisions of the EU pharmacovigilance legislation to reduce the administrative burden on companies1.